When was Re-gen Active Lab founded?

Re-gen Active Lab was founded in 2018 and raised its 1st funding round 6 years after it was founded.

Where is Re-gen Active Lab located?

Re-gen Active Lab is headquartered in Irving, United States.

How many employees does Re-gen Active Lab have?

As of Jun 30, 2026, the latest employee count at Re-gen Active Lab is 3.

Is Re-gen Active Lab a funded company?

Re-gen Active Lab is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Jan 02, 2024.

When was the latest funding round of Re-gen Active Lab?

Re-gen Active Lab's latest funding was a $***** Seed round on Jan 02, 2024, with participation from 0 investor. Its primary sector is Dermatology. In United States, the Dermatology sector has seen $197M in funding in 2026 to date.

Where does Re-gen Active Lab rank among its competitors?

Re-gen Active Lab ranks 1654th amongst 2569 active competitors, of which 864 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Re-gen Active Lab?

Re-gen Active Lab's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Immuneel secured the most recent funding round in June, 2026.

Re-gen Active Lab - 2026 Company Profile, Team, Funding & Competitors

Re-gen Active Lab is a seed company based in Irving (United States), founded in 2018 by Marty Porter. It operates as a Developer of regenerative medicine. Re-gen Active Lab has raised $2.3M in funding. The company has 2569 active competitors, including 864 funded and 628 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Company Details

Regenactive lab is the developer of regenerative medicine. The company has developed injectable and topical regenerative medicine by using its proprietary technology. Its products are activeshot, activeflow, activepro, and regenbalm among others. The company also developed the whartons jelly which is the gel-like tissue that provides structural support, cushioning and lubrication in the body.

Website: regenactivelab.com
Social
Email ID: *****@regenactivelab.com
Phone Number: +1 **********

Key Metrics

Founded Year

2018

Location

Irving, United States

Stage

Seed

Total Funding

$2.3M in 1 round

Latest Funding Round

Seed, Jan 02, 2024, $*****

Ranked

1654^th among 2569 active competitors

Employee Count

3 as on Jun 30, 2026

Similar Companies

LEO Pharma & 170 more

View Re-gen Active Lab's full profile

Re-gen Active Lab has raised a total funding of $2.3M over 1 round.

Here is the list of recent funding rounds of Re-gen Active Lab:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 02, 2024	8071061	Seed	5146640	8224088	9075452	6758235

Access funding benchmarks and valuations. Sign up today!

View details of Re-gen Active Lab's funding rounds and investors

The founders of Re-gen Active Lab is Marty Porter.

Here are the details of Re-gen Active Lab's key team members:

Marty Porter: Co-Founder & COO of Re-gen Active Lab.
Contact Info: 1 email address

View details of Re-gen Active Lab's Founder profiles and Board Members

Re-gen Active Lab's employee count trend

Re-gen Active Lab has 3 employees as of Jun 26. Here is Re-gen Active Lab's employee count trend over the years:

Employee count trend for Re-gen Active Lab

Uncover Re-gen Active Lab's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Re-gen Active Lab include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Re-gen Active Lab, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	73/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Domain Associates, Fidelity Investments & 19 others	72/100
6th	LEO Pharma 1908, Copenhagen (Denmark), Late Stage	Developer of drugs for treating dermatology diseases	$560M	Nordic Capital	71/100
7th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
8th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
9th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
10th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Livzon Pharmaceutical & 5 others	71/100
1654th	Re-gen Active Lab 2018, Irving (United States), Seed	Developer of regenerative medicine	$2.3M	-	27/100